Scotia Capital’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
Other funds holding OTLK
Scotia Capital's OTLK Position: Q3 2026 in Review
Scotia Capital reduced its Outlook Therapeutics (OTLK) stake by 43% in Q3 2026, selling an estimated $19.1K and leaving 26,300 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #973.
Scotia Capital first reported a position in OTLK in Q2 2023 and has held it in 13 quarters since. The position peaked at $283K in Q1 2024. 82 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.
- Scotia Capital held 26,300 shares of Outlook Therapeutics worth $15.1K as of Q3 2026.
- Scotia Capital sold 20,000 Outlook Therapeutics shares in Q3 2026, an estimated $19.1K.
- Outlook Therapeutics made up ﹤0.01% of Scotia Capital's portfolio in Q3 2026, its #973 holding.
- Scotia Capital first reported a position in Outlook Therapeutics in Q2 2023 and has held it in 13 quarters since.
- Scotia Capital's Outlook Therapeutics position peaked at $283K in Q1 2024.
- 82 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.
Based on Scotia Capital's 13F filing for Q3 2026, filed 10 Nov 2026.